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important in mediating the mitogenic and anti-apoptotic ac-Renal ischemia-reperfusion increases endothelial VEGFR-2
tions of VEGF on endothelial cells, thereby preserving thewithout increasing VEGF or VEGFR-1 expression.
integrity of the endothelium and the potential for blood supplyBackground. Hypoxia is a potent stimulus to angiogenesis.
to ischemic tissues.Expression of the angiogenic growth factor vascular endothe-
lial growth factor (VEGF) and its receptors (VEGFR-1 and
VEGFR-2) is up-regulated by hypoxia in a variety of organs
and cell lines. We have previously reported that VEGF expres-
Vascular endothelial growth factor (VEGF) is a potentsion is not increased in renal ischemia-reperfusion injury, al-
though tubular cells concentrate VEGF at their basolateral multifunctional cytokine that promotes angiogenesis,
surface. In this study we assess whether altered VEGF receptor increases vascular permeability and is chemotactic for
expression compensates for the lack of VEGF regulation dur- monocytes [1, 2]. VEGF has been shown to have a role
ing renal ischemia-reperfusion injury.
in a wide variety of situations including embryogenesis,Methods. VEGFR-1 mRNA expression was assessed by
placental growth, tumor growth, diabetes, wound heal-Northern blotting and semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR). VEGFR-2 mRNA ex- ing, inflammatory responses and tissue remodeling [2, 3].
pression was analyzed by Northern blotting and in situ hybrid- There are two well established receptors for VEGF pre-
ization (ISH), while VEGFR-2 protein expression was studied viously described as flt-1 and KDR/flk-1, and now desig-using immunohistochemistry. VEGF mRNA expression was
nated VEGF receptor-1 (VEGFR-1) and VEGF recep-assessed by ISH.
Results. VEGFR-2 mRNA and protein expression were up- tor-2 (VEGFR-2), respectively [4–6]. VEGF also binds
regulated without an increase in VEGF or VEGFR-1 expres- to the co-receptors neuropilin-1 and neuropilin-2 [7, 8].
sion. Normal kidneys showed low-level VEGFR-2 mRNA and VEGFR-1 and VEGFR-2 are type III tyrosine kinases
protein expression in glomerular and peritubular endothelium.
predominantly expressed on endothelial cells. VEGF actsFollowing ischemia and ischemia-reperfusion, a marked in-
via these receptors stimulating anti-apoptotic actions [9, 10]crease in VEGFR-2 mRNA and protein expression was seen
(2- to 4-fold). Most prominent was VEGFR-2 mRNA up-regu- and endothelial cell division and migration [11–13].
lation in the glomerulus although, surprisingly, increased pro- Studies performed in vitro have demonstrated similar-
tein was not demonstrated here. ISH showed that VEGF
ities between the regulation of VEGF, VEGFR-1 andmRNA was not up-regulated in this model, confirming our
erythropoietin (EPO). The expression of VEGF mRNAprevious findings for VEGF.
Conclusion. VEGF and VEGFR-1 expression are not in- has been shown to be markedly increased in a variety
creased by renal ischemia and ischemia-reperfusion injury. of cells when they are made hypoxic or when hypoxia-
Instead, endothelial expression of VEGFR-2 is increased. mimicking techniques are used [14–20]. Evidence sug-VEGFR-2 up-regulation in renal ischemia-reperfusion may be
gests that this occurs via the activation of a heme-con-
taining, oxygen-sensing receptor that ultimately leads to
the induction of the transcription factor hypoxia-induc-1 Current address: Baylor College of Medicine, Division of Nephrology,
1 Baylor Plaza, Houston, TX, 77030, USA. ible factor-1 (HIF-1) [21]. Studies performed in vivo also
have shown that VEGF mRNA increases in response toKey words: vascular endothelial growth factor, angiogenesis, hypoxia,
organ storage, I/R injury, mitogenesis. hypoxia in most organs [19, 22–24]. The kidney appears to
differ in this regard as we [1] and others [25, 26] have pre-
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in contrast to the findings in other organs. The reason comparison. Four rats were used at each time point,
giving a total of sixteen left ischemia-reperfused (LIR)for this difference is unknown.
Like VEGF, the VEGFR-1 promoter region contains kidneys, and sixteen contralateral right normal (RN)
kidneys. Four normal and two sham-operated kidneysa heptamer sequence matching the HIF-1 consensus-bind-
ing site. Mutations of this site decrease transcriptional were used also for comparison.
activation by hypoxia [27]. Although the VEGFR-2 pro-
Synthesis of VEGF and VEGFR-2 riboprobesmoter region has no HIF-1 consensus, it does contain
potential nuclear factor-B (NF-B) and activator pro- These were performed as previously described [32, 33].
Briefly, sense and anti-sense RNA probes for VEGFtein-2 (AP-2) sites [28]. While the hypoxia-responsive-
ness of VEGFR-2 remains contentious in vitro, this is and VEGFR-2 were generated by in vitro transcription
(Promega, Madison, WI, USA). Linearized templatenot the case in vivo where several studies have shown
that it is up-regulated. Up-regulation of mRNA for both (500 ng) was added to a reaction mixture of transcription
buffer (final volume 20 L) containing 6 mmol/L dithio-VEGFR-1 and VEGFR-2 has been demonstrated in rat
lungs exposed to acute and chronic hypoxia [24] and threitol (DTT), 333mol/L each of adenosine 5-triphos-
phate (ATP), carbamylated protein (CTP) and guanosinein rat hearts from a myocardial infarction model [29].
VEGFR-1 protein was increased in brain tissue from 5-triphosphate (GTP), 12 mol/L uridine triphosphate
(UTP), 100 Ci [33P]UTP (2,000 Ci/mmol, New-Dupont,rat cerebral infarction models [30]. VEGFR-2 but not
VEGFR-1 mRNA and protein have been reported to Boston, MA, USA), 20 U RNAsin (Boehringer-Mann-
heim, Mannheim, Germany) and 20 mU RNA polymer-be up-regulated in a mouse model of ischemia-induced
retinal neovascularization [31]. ase (Boehringer-Mannheim). The reaction mixture was
incubated at 37C for 90 minutes, after which the DNADespite several studies in a variety of organs, there are
few reports in the literature examining VEGF receptor template was digested with 1 U RNAse-free DNAse for
15 minutes. The riboprobe was precipitated by ammo-expression in renal hypoxia or ischemia-reperfusion. In
addition, the lack of hypoxia-responsiveness demonstrated nium acetate and ethanol using yeast tRNA as a carrier
and then reconstituted in 100 L of water. Purified ribo-by VEGF in renal ischemia-reperfusion [1] suggests that
there may be a response mediated at the receptor level. probe length was adjusted to approximately 150 bases
by alkaline hydrolysis.The present studies demonstrate that VEGFR-2 mRNA
and protein expression are up-regulated in renal ische-
In situ hybridization for VEGF and VEGFR-2 mRNAmia-reperfusion injury, while VEGF and VEGFR-1 ex-
pression remain unchanged. These data suggest that Four micrometer-thick sections were cut from para-
formaldehyde-fixed paraffin-embedded kidney tissue. Tis-signaling through VEGFR-2 may be important in the
survival of endothelial cells in the kidney following ische- sue sections were dewaxed, rehydrated, and equilibrated
in P buffer [50 mmol/L Tris-HCl, pH 7.5, 5 mmol/L ethyl-mic injury.
enediaminetetraacetic acid (EDTA)], and then incu-
bated in 125 g/mL Pronase E (Sigma Chemical Co., St.
METHODS
Louis, MO, USA) in P buffer for 10 minutes at 37C.
Ischemia-reperfusion injury Sections were then washed in 0.1 mol/L sodium phos-
phate buffer (pH 7.2), briefly refixed in 4% paraformal-Outbred male Sprague-Dawley rats were purchased
from Monash University Central Animal Services (Clay- dehyde for 10 minutes, rinsed in milliQ water, dehy-
drated in 70% ethanol, and air-dried. Hybridizationton, Victoria, Australia) and given free access to food
and water. The renal ischemia-reperfusion model was buffer containing 2  104 cpm/L riboprobe in 300
mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.5), 10 mmol/Lproduced as previously reported [1]. Briefly, rats were
anaesthetized with intraperitoneal injections of sodium Na2HPO4, 5 mmol/L EDTA (pH 8.0), 1  Denhardt’s
solution, 50% formamide, 17 mg/mL yeast RNA, andpentobarbitone (6 mg/100 g body weight; Nembutal, Ab-
bott Laboratories, North Ryde, NSW, Australia) and 10% wt/vol dextran sulfate was heated to 85C for five
minutes. A 25 L aliquot of this solution was then ap-a midline peritoneal incision was made. The left renal
pedicle was clamped for 40 minutes using non-traumatic plied to each tissue section under coverslips. Hybridiza-
tion of tissue to the riboprobe was performed overnightvascular clamps. Variable periods of reperfusion fol-
lowed (0, 20, 40 and 80 min) and the left kidneys were at 60C in 50% formamide-humidified chambers. Sense
probes were used on a further set of tissue sections asthen harvested and processed. The 0 minute time point,
therefore, refers to the ischemic kidneys that were not controls. After hybridization, slides were washed in 2 
standard sodium citrate (SSC) containing 50% form-reperfused, whereas the 20, 40, and 80 minute time points
indicate 40 minutes of ischemia followed by the stated amide prewarmed to 50C to remove coverslips. Sections
were then washed for one hour at 55C, rinsed threeperiods of reperfusion. The right contralateral kidneys
were removed simultaneously with the left and used for times in RNAse buffer (10 mmol/L Tris-HCl, pH 7.5,
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1 mmol/L EDTA, pH 8.0, 0.5 mol/L NaCl), and then one hour at 65C using Rapid Hyb buffer (Amersham
incubated with RNAse A (150 g/mL) for one hour at International, Little Chalfont, Buckinghamshire, UK).
37C. Sections were later washed in 2  SCC for 45 Inserts were labeled using the Megaprime DNA Label-
minutes at 55C, dehydrated in graded ethanol, air-dried, ing System (Amersham) and added to fresh Rapid Hyb
and exposed to Kodak X-Omat autoradiographic film buffer at 2  106 counts/mL hybridization fluid. Mem-
(Eastman Kodak, Rochester, NY, USA) for one to three branes were hybridized for two hours at 65C and then
days. Slides were then dipped in Ilford K5 nuclear emul- washed three times for 20 minutes each [first wash in
sion (Ilford, Mobberley, UK), stored in a light-free box (2  SSC)/0.1% sodium dodecyl sulfate (SDS) at 65C,
with dessicant at room temperature for two to three second wash in (1  SSC)/0.1% SDS at 65C, third wash
weeks, and developed in Kodak D19, followed by fixa- in (0.1  SSC)/0.1% SDS at room temperature], prior
tion with Ilford Hypam. Sections were then stained with to exposure to x-ray film (Kodak). Bands were analyzed
hematoxylin and eosin (H&E) for examination under by densitometry (Molecular Dynamics Computing Den-
light microscopy. sitometer, Model 300A; Sunnyvale, CA, USA) using Im-
ageQuant Software (version 3.0).
Isolation of total RNA
Total RNA was extracted from tissues using Trizol Semiquantitative RT-PCR
(Life Technologies, Gibco BRL, Melbourne, Australia). This assay was performed as previously described [1]
Whole tissue samples were homogenized in Trizol using using a modification of published methods [37, 38].
a homogenizer (pro200; Proscientific Inc., Oxford, CT, Briefly, first strand cDNA was synthesized from 1 g of
USA). Sample RNA levels were quantitated by reading total RNA using AMV-reverse transcriptase (Promega).
the absorbance at 260 nm. Final samples were stored The subsequent PCR reaction used the VEGFR-1 prim-
at 70C until required for Northern blot analysis and ers already described for Northern blotting experiments,
semiquantitative reverse transcription-polymerase chain producing a 240 bp product. The PCR reaction was inter-
reaction (RT-PCR). rupted at five cycle intervals and the products were ana-
lyzed. Levels of VEGFR-1 mRNA expression were as-Northern blotting
sessed by comparing the density of bands on 2% agarose
Vascular endothelial growth factor receptor-1 and gels, and the cycle of first appearance of PCR products.
VEGFR-2 cDNA inserts were PCR-amplified from re- Amplification of a 254 base pair product representing
verse transcribed rat kidney RNA using primer sequences glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
obtained from the known rat receptor sequences (Gene-
was used to check the efficiency of the reverse transcrip-
bank accession nos. D28498 and U93306, respectively)
tion and of the PCR reaction. GAPDH PCR profiles[34, 35]. Primers for the VEGFR-1 insert (forward 5-CAA
were compared and equalized. Duplicate amplificationsGGGACTCTACACTTGTC-3 and reverse 5-CCGA
were performed for each sample and the results wereATAGCGAGCAGATTTC-3) resulted in a 240 bp prod-
shown to be reproducible.uct corresponding to a portion of the extracellular do-
main (amino acid residues 305–384). Primers for the Immunohistochemical staining of rat kidney
VEGFR-2 insert were as described by Wen and co-work- for VEGFR-2
ers [34] (forward 5-GCCAATGAAGGGGAACTGA
Paraffin-embedded rat kidney tissue sections (4 m-AGAC-3 and reverse 5-TCTGACTGCTGGTGATG
thick) were fixed in 4% paraformaldehyde and analyzedCTGTC-3). These produced a 537 bp product corre-
for the presence of VEGFR-2 protein. The primary anti-sponding to the intracellular, amino terminal end of the
body used was N-931 (Santa Cruz, Biotechnology Inc.,tyrosine kinase domain of the receptor (amino acid resi-
Santa Cruz, CA, USA), a polyclonal anti-mouse VEGFR-2dues 870–1049). The PCR products were cloned into
antibody directed against amino acid residues 931–997.pGEM-T easy (Promega) and the DNA sequences con-
Endogenous peroxidase was quenched with 4% hydro-firmed by sequencing. The VEGFR-1 insert was excised
gen peroxide in methanol. Non-specific binding wasfrom the vector using the restriction enzyme EcoR1 (Pro-
blocked using 10% swine serum prior to incubation withmega), while the VEGFR-2 insert was excised using NcoI
primary antibodies overnight at 4C (concentration ofand SalI (Promega). A mouse GAPDH insert that cross-
1 g/mL). Negative controls used normal rabbit IgGhybridizes with rat GAPDH was obtained as a 1.2 kb
(Sigma) in place of N-931, at the same concentration asPstI fragment in clone pHcGAP [36].
the primary antibody. A peroxidase kit was used forTotal RNA samples were fractionated on a 1% aga-
subsequent steps (LSAB 2 Peroxidase kit; Dako, Car-rose-formaldehyde gel and transferred to Genescreen
pinteria, CA, USA) followed by development of stainingPlus membranes (NEN Life Sciences, Boston, MA, USA).
with diaminobenzidine (DAB; Dako). CounterstainingMembranes were cross-linked using a Stratalinker (Stra-
tagene, La Jolla, CA, USA) and then prehybridized for was performed with hematoxylin.
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Fig. 1. In situ hybridization for vascular en-
dothelial growth factor (VEGF) mRNA in
normal, ischemic and control kidneys probed
with anti-sense. Panels are in pairs; bright field
photographs of tissues stained with hematoxy-
lin and eosin on the left with corresponding
dark field images on the right. A positive signal
is shown by dark granules on bright field im-
ages, with bright granules on corresponding
dark field photographs. (A) Normal rat cortex
showing VEGF mRNA expression in podo-
cytes (arrows) with low-level expression in tu-
bular epithelial cells. (B) The cortex from ische-
mic kidneys with no reperfusion was similar
to that of normal kidneys. (C ) Medulla from
normal rat kidneys showing VEGF mRNA
expression in tubular epithelial cells (arrows).
(D) The appearance in ischemic kidneys was
similar. All ischemic, ischemia-reperfused (not
shown), and control kidneys had a similar ap-
pearance. (E ) Normal kidney probed with a
sense riboprobe. There was no difference in
VEGF mRNA expression by in situ hybridiza-
tion between the various groups of kidneys.
Magnifications: 160.
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Statistics
Northern blots were compared using ANOVA and
Dunnett’s multiple comparison test. A P value 0.05
was considered to be significant.
RESULTS
VEGF mRNA expression
We have previously reported the expression of VEGF
protein (by immunohistochemistry and Western blotting
analysis) and mRNA (by semiquantitative RT-PCR and
Northern blotting analysis) in this model [1]. To confirm
these findings, VEGF mRNA was assessed by in situ
hybridization (Fig. 1). In normal rat kidney, VEGF
mRNA was localized predominantly to glomerular epi-
thelial cells (Fig. 1A) and medullary tubular epithelial
cells (Fig. 1C). These areas showed prominent VEGF
mRNA expression. Ischemic (Fig. 1B), ischemia-reper-
fused (Fig. 1D), and control kidneys (not shown) all
demonstrated a similar appearance to the normal kid-
neys (Fig. 1, A, C). Use of a sense riboprobe showed Fig. 2. Semiquantitative RT-PCR of mRNA, ischemia-reperfusion
no signal (Fig. 1E). These findings were consistent with model RT-PCR profiles for VEGFR-1 mRNA (upper six panels) and
GAPDH mRNA (lower six panels) from normal and ischemic kidneysresults previously reported [1], indicating that there was
(40 min ischemia, no reperfusion). N1, 2 and 3 represent differentno difference in VEGF mRNA expression between the normal kidneys. I-1, -2 and -3 represent different ischemic kidneys.
various groups. Samples were titrated to obtain equal intensity bands representing
GAPDH mRNA at 25 PCR cycles. The PCR product representing
VEGFR-1 mRNA is demonstrated in the upper six panels (size 240 bp).VEGFR-1 mRNA expression
Bands representing VEGFR-1 mRNA first appeared at 35 PCR cycles
VEGFR-1 mRNA expression was assessed by semi- with appearances between all groups being similar. Profiles for PCR
products from the reperfused kidneys (not shown) had a similar appear-quantitative RT-PCR (Fig. 2) and Northern blotting
ance to the ischemic, normal and control kidneys.
analysis (Fig. 3). Both of these methods showed no dif-
ference in VEGFR-1 mRNA expression between the
various groups of kidneys. By semiquantitative RT-PCR,
the band representing VEGFR-1 mRNA first appeared with normal and control kidneys. Northern blotting anal-
at 35 cycles (Fig. 2). Bands from normal, ischemic and ysis demonstrated a single mRNA species of approxi-
ischemia-reperfused kidneys showed no significant differ- mately 6.8 kb (Fig. 3A), consistent with the known size
ence when assessed by densitometry. The PCR profiles for VEGFR-2 mRNA [4, 5]. Samples from normal and
for VEGFR-1 and GAPDH were similar for all kidneys. control kidneys showed only a faint band for VEGFR-2
Semiquantitative RT-PCR experiments for VEGFR-1 mRNA. By contrast, ischemic and ischemia-reperfused
mRNA expression were performed on three groups of kidneys showed a prominent band (Fig. 3A). Densito-
rats and shown to be reproducible. Northern blotting metric analysis of Northern blots demonstrated that
analysis confirmed these findings (Fig. 3), with similar VEGFR-2 mRNA expression in the ischemic and ische-
renal VEGFR-1 mRNA expression being demonstrated mia-reperfused kidneys was increased two- to fourfold
in all rats. Densitometric analysis (Fig. 3B) showed no compared to normal and control kidneys (Fig. 3B). The
change in VEGFR-1 mRNA expression following renal level of VEGFR-2 mRNA expression was similar in all
ischemia and ischemia-reperfusion. Northern blotting the kidneys subjected to ischemia, regardless of the re-
analysis was performed on three rats at each time point, perfusion time (0, 20, 40 or 80 min).
with similar results. In situ hybridization demonstrated VEGFR-2 mRNA
expression in normal glomeruli localized predominantly
VEGFR-2 mRNA expression to the endothelial cells (Fig. 4 A, C, E). In the inter-
stitium, peritubular capillaries also showed VEGFR-2VEGFR-2 mRNA expression was assessed by North-
ern blotting analysis (Fig. 3) and in situ hybridization mRNA expression (Fig. 5A), although this was less
prominent than that seen in glomerular endothelial cells.(Figs. 4 and 5). Both techniques showed VEGFR-2
mRNA expression to be markedly up-regulated in the These appearances were consistent with the notion that
VEGFR-2 is predominantly expressed on endothelialischemic and ischemia-reperfused kidneys compared
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Fig. 3. Northern blotting analysis of total RNA
samples from the ischemia-reperfusion model
Northern blots demonstrating mRNA for
VEGFR-1 and VEGFR-2 relative to GAPDH
mRNA. A single mRNA species was identi-
fied for each receptor. VEGFR-1 was at 7.2 kb
and VEGFR-2 at 6.8 kb. (A) Normal kidney
(N; lane 1), representative contralateral right
normal kidneys (RN; lanes 2 and 3), left ische-
mia-reperfused kidneys (LIR; lanes 4-7). 0, 20,
40 and 80 refer to reperfusion time in minutes.
The Northern blot is representative of three
separate experiments. VEGFR-1 expression ap-
pears similar in all samples whereas VEGFR-2
mRNA expression is increased in the LIR kid-
neys. (B) Densitometric analysis of the North-
ern blots in panel A. Symbols are: Results are
from three separate rats, at each time point.
Symbols are: ( ) VEGFR-1 GAPDH; ()
VEGFR-2 GAPDH. VEGFR-2 mRNA levels
are increased in the LIR kidneys (2- to 4-fold)
compared to normal and control kidneys.
VEGFR-1 mRNA expression is unchanged.
Data are mean  SD (* P  0.05 vs. normal;
Dunnett’s multiple comparison test).
cells. A marked increase in VEGFR-2 mRNA expression consistent with the in situ hybridization results (Fig. 6
D, F). Normal (Fig. 6 C, D) and control kidneys (notwas seen in the ischemic and ischemia-reperfused kid-
shown) demonstrated slight glomerular (Fig. 6C) andneys in both the glomerulus (Fig. 4 B, D, F) and renal
peritubular (Fig. 6D) endothelial cell staining. These ap-interstitium (Fig. 5 B, C). Glomeruli from ischemic kid-
pearances were similar to those that we have previouslyneys (Fig. 4 B, D, F) showed marked expression of
reported in normal rat kidney using the N-931 antibodyVEGFR-2 mRNA compared to normal (Fig. 4 A, C, E)
[39]. It was difficult to identify any change in VEGFR-2and control kidneys (not shown) in a pattern consistent
protein in glomeruli from ischemic (Fig. 6E) and ische-with localization to the glomerular endothelial cells.
mia-reperfused kidneys (not shown) by immunohisto-However, the signal was so intense that it proved impos-
chemistry using the N931 antibody. In the interstitiumsible to determine whether glomerular mesangial cells,
of ischemic (Fig. 6F) and ischemia-reperfused kidneysin particular, expressed VEGFR-2 mRNA. The cortical
(not shown), however, VEGFR-2 was increased and ap-(Fig. 5C) and medullary interstitium (Fig. 5B) of ische-
peared to be predominantly expressed on peritubularmic kidneys also showed increased VEGFR-2 mRNA
capillary endothelium. In addition, there was some gen-expression compared to normal (Fig. 5A) and control
eralized staining of renal tubular epithelium in the kid-kidneys (not shown), with localization predominantly
neys from all groups, particularly in the medulla (Fig. 6to peritubular capillary endothelium. Tubular epithelial
D, F).cells also demonstrated some evidence of VEGFR-2
The immunohistochemical appearances in control kid-mRNA expression, with some of the ischemic tubules
neys (right contralateral non-ischemic kidneys; not shown)clearly showing a signal overlying these cells rather than
resembled those of normal kidneys (Fig. 6 C, D). Nega-peritubular capillary structures (Fig. 5 B, C).
tive controls demonstrated no significant staining (Fig.
6 A, B).VEGFR-2 protein expression
VEGFR-2 protein expression was assessed immuno-
DISCUSSIONhistochemically using the polyclonal antibody, N-931.
It showed interstitial staining in normal, ischemic and These studies demonstrate the up-regulation of
VEGFR-2 mRNA and protein in a rat model of renalischemia-reperfused (data not shown) kidneys that was
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Fig. 4. In situ hybridization for VEGFR-2
mRNA in normal (A, C and E ) and ischemic
(B, D and F ) rat kidney. Glomerular appear-
ances. (A–D) Dark field images. (E and F)
Bright field images stained with hematoxylin
and eosin, corresponding to panels C and D,
respectively. Normal glomeruli (A, C and E)
showed low-level VEGFR-2 mRNA expres-
sion, localized to glomerular endothelium
(arrows). By contrast, ischemic kidneys (B,
D and F) showed a marked increase in
VEGFR-2 mRNA expression (arrows). The
appearances are consistent with localization
to glomerular endothelium, although the in-
tensity of the signal makes it difficult to say
with certainty whether or not other glomeru-
lar cells are positive. All the ischemic kidneys
in the figure were not subjected to reperfusion,
although reperfused kidneys (not shown) had
a similar appearance. Ischemic rat kidney
probed with sense demonstrated virtually no
signal (not shown). Magnifications: A and B
150, C–F 350.
ischemia-reperfusion injury. By contrast, VEGF and or low ambient oxygen concentration [40]. In this circum-
stance, VEGF mRNA was increased in tubular cells butVEGFR-1 mRNA expression were not increased in re-
sponse to the injury. These findings occurred despite the decreased in the glomerulus. VEGFR-2 was unchanged
and VEGFR-1 was increased in the vasculature. Thesepresence of HIF-1 binding sites in the promoter regions
of the VEGF and VEGFR-1 genes, and the lack of such results suggest that there may be a different signaling
pathway for hypoxia induced by reduced oxygen loadinga site in the promoter region of the VEGFR-2 gene
[17, 27]. We have previously reported the absence of of hemoglobin in the lungs compared with ischemia,
where local blood flow is severely reduced and leads,increased VEGF mRNA and protein in this model [1],
and have now confirmed this finding using in situ hybrid- secondarily, to tissue hypoxia.
In situ hybridization studies suggested that VEGFR-2ization. These results are in contrast to the findings re-
ported in other organs such as the lung and heart, which mRNA expression in the interstitium was predominantly
localized to endothelial cells, consistent with the knownshow up-regulation of both VEGF receptors [24] in addi-
tion to VEGF [22–24]. They are not consistent with mod- expression of this receptor [41, 42]. Peritubular capillary
endothelium showed a marked increase in VEGFR-2els where renal hypoxia is induced with carbon monoxide
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Fig. 5. In situ hybridization for VEGFR-2
mRNA in normal (A) and ischemic (B and
C ) rat kidney. Interstitial appearances. Panels
are in pairs; bright field photographs on the
left corresponding with dark field images on
the right. Normal kidneys (A) showed low-
level VEGFR-2 mRNA expression, localized
to peritubular capillaries (arrows). Ischemic
kidneys (B and C) showed a marked increase
in VEGFR-2 mRNA expression in these
structures (arrows). In addition, some of the
ischemic tubules appeared to show a signal
for VEGFR-2 mRNA (arrowheads, C), which
was not evident in the negative controls. All
the ischemic kidneys demonstrated in the fig-
ure were not subjected to reperfusion al-
though reperfused kidneys (not shown) had
a similar appearance. Ischemic rat kidney
probed with sense (not shown) demonstrated
virtually no signal. Magnifications: A 350, B
400, C 500.
mRNA expression following ischemia, and ischemia- genic effects of locally released VEGF to these cells.
Although tubular cell production of VEGF protein is notreperfusion. In addition, there appeared to be some evi-
dence of VEGFR-2 mRNA expression in tubular epithe- increased during ischemia-reperfusion, we have pre-
viously reported that VEGF in tubular cells is redistrib-lial cells, although this was much less prominent than
the endothelial expression. We have previously shown uted to the basolateral surface of the cells [1]. This could
act to protect the endothelium adjacent to viable tubularevidence supporting VEGFR-2 expression by renal tu-
bular epithelial cells both in vitro and in vivo [39]. From epithelial cells, so preserving their capillary supply when
blood flow is re-established. Several reports have clearlythe current study, however, the in situ hybridization
findings show that the endothelium is the predominant demonstrated a role for VEGF in preventing endothelial
cell apoptosis via stimulation of VEGFR-2 [9, 10]. Thissite of VEGFR-2 expression in the renal interstitium.
Immunohistochemical studies using the N-931 polyclonal would be an obvious role for tubular secretion of VEGF,
since survival of a tubular cell following hypoxic injuryantibody showed increased VEGFR-2 expression in the
peritubular capillaries, consistent with the in situ hybrid- is likely to be critically dependent on the survival of the
adjacent endothelium. Increased nitric oxide expressionization findings.
The function of increased expression of VEGFR-2 by mediated through VEGFR-2 and endothelial nitric oxide
synthase (eNOS) [43–46] also may be of importance inperitubular capillaries is probably to direct the angio-
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Fig. 6. Immunohistochemical staining for
VEGFR-2 in normal and ischemic rat kidneys.
Negative controls stained using normal rabbit
serum instead of rabbit polyclonal antibody
(A and B). Normal kidney cortex and medulla
stained with N-931 antibody (C and D). There
is staining consistent with peritubular capillar-
ies (arrows) in the medulla (D) in normal kid-
neys and within the glomerular capillaries (C,
arrows). Ischemic kidney showed little change
in glomerular staining for VEGFR-2 (E ) but
more obvious increased staining in the peritu-
bular regions (F, arrows), consistent with peri-
tubular capillary expression. Magnifications:
A, C, E 350, B, D, F 400.
altering renal hemodynamics. Furthermore, alterations The glomerulus also showed a marked increase in
VEGFR-2 mRNA expression following 40 minutes ofin vascular permeability mediated through VEGFR-2
[47] may contribute to the extensive edema and extrava- ischemia, which persisted with reperfusion of up to 80
minutes. Interestingly, this was not associated with ansation seen in the model, although the precise mechanism
for this effect remains unclear, as studies have demon- apparent increase in VEGFR-2 protein expression by
immunohistochemical staining with the N-931 polyclonalstrated [48]. More recent reports have clearly demon-
strated a protective role for VEGF on the peritubular antibody. Such a profound up-regulation of VEGFR-2
mRNA within the glomerulus demonstrates that isch-endothelium in models of tubulointerstitial injury [49].
Results of in vitro studies suggest that this effect is likely emia-reperfusion injury affects both glomerulus and tu-
bulointerstitium, although most studies have focused onto be mediated through VEGFR-2 [2, 50].
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liferation by a peptide corresponding to the exon 7-encoded do-the latter. The absence of any detectable increase in
main of VEGF165. J Biol Chem 272:31582–31588, 1997
protein expression suggests that VEGFR-2 may not have 9. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth
a significant role within the glomerulus in the response factor induces expression of the antiapoptotic proteins Bcl-2 and
A1 in vascular endothelial cells. J Biol Chem 273:13313–13316, 1998to ischemia and ischemia-reperfusion, despite the in-
10. Gerber HP, McMurtrey A, Kowalski J, et al: Vascular endothe-crease in mRNA. lial growth factor regulates endothelial cell survival through the
In summary, VEGFR-1 and VEGFR-2 expression phosphatidylinositol 3-Kinase/Akt signal transduction pathway.
J Biol Chem 273:30336–30343, 1998were examined in normal rat kidney, and in a renal
11. Connolly DT, Olander JV, Heuvelman D, et al: Human vascularischemia-reperfusion model. Despite several studies in a permeability factor. Isolation from U937 cells. J Biol Chem 264:
variety of organs, there are no reports examining VEGF 20017–20024, 1989
12. Keck PJ, Hauser SD, Krivi G, et al: Vascular permeability factor,receptor expression in this model. VEGFR-2 mRNA ex-
an endothelial cell mitogen related to PDGF. Science 246:1309–pression in the glomerulus and in peritubular capillary 1312, 1989
endothelium was shown to be markedly up-regulated by 13. Leung DW, Cachianes G, Kuang WJ, et al: Vascular endothelial
growth factor is a secreted angiogenic mitogen. Science 246:1306–renal ischemia and ischemia-reperfusion, although we
1309, 1989could not demonstrate increased VEGFR-2 protein ex-
14. Namiki A, Brogi E, Kearney M, et al: Hypoxia induces vascular
pression within the glomeruli. By contrast, renal VEGFR-1 endothelial growth factor in cultured human endothelial cells.
J Biol Chem 270:31189–31195, 1995mRNA expression was unaltered. VEGFR-2 up-regula-
15. Iijima K, Yoshikawa N, Connolly DT, Nakamura H: Humantion in the renal tubules during renal ischemia-reperfu-
mesangial cells and peripheral blood mononuclear cells produce
sion injury may be important in directing the mitogenic, vascular permeability factor. Kidney Int 44:959–966, 1993
16. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced tran-anti-apoptotic and vascular permeability actions of VEGF
scriptional activation and increased mRNA stability of vascularreleased by ischemic tubular epithelial cells to adjacent
endothelial growth factor in C6 glioma cells. J Biol Chem 270:
endothelial cells, thereby preserving the potential for 19761–19766, 1995
capillary blood supply and promoting tubular cell sur- 17. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional
regulation of the rat vascular endothelial growth factor gene byvival and recovery.
hypoxia. J Biol Chem 270:13333–13340, 1995
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